Eli Lilly's Trulicity beats growth expectations
Just like Novo Nordisk, Eli Lilly has demonstrated that diabetes drugs sell well.
by marketwire, translated by daniel pedersen
Novo Nordisk’s big US-based competitor, Eli Lilly, has exceeded the sales expectations of its leading diabetes type 2 drug, just as its Danish counterpart could announce the same thing in its financial report on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly prepares for FDA rejection of eczema treatment
For subscribers
